



DISCOVER

DEVELOP

DIAGNOSE



**Asuragen** is a molecular diagnostics company using genomics to drive better patient management through best-in-class clinical testing solutions. With a **pioneering position in miRNA**, Asuragen has assembled cutting edge technologies to **discover**, **develop** and **commercialize** diagnostic products and clinical testing services. Our experienced team utilizes these capabilities to operate with efficiency and flexibility with our internal R&D programs as well as with our companion diagnostic partners.

Building on the company's heritage, Asuragen has developed a reputation as a **world class molecular diagnostics company** and has created a culture driven by nimble, innovative and determined teams of scientists and professionals inspired to improve patient management through molecular diagnostics.



# DISCOVER

## Discovering Novel Molecular Signatures


Our scientific team has discovered molecular signatures that have translated to first-in-class products that provide solutions for unaddressed challenges in clinical practice. Made possible through world-renowned science, Asuragen has become a proven force in molecular biology by discovering new biomarkers and diagnostics products for our partners as well as our own internal pipeline. As pioneers in the application of miRNA technology, Asuragen developed a pancreatic cancer test that is the world's first miRNA-based diagnostic test.

### miRInform<sup>®</sup> Pancreas

- Utilizes a miRNA proprietary signature to improve the diagnosis of pancreatic cancer (PDAC)
- Resolves inconclusive pre-operative diagnoses to improve surgical treatment decisions

### miRInform<sup>®</sup> Thyroid

- Aids in the resolution of inconclusive cytopathology
- Detects 17 well-characterized RNA and DNA markers plus novel miRNAs correlated with thyroid cancer
- Helps optimize surgical approach and may help avoid surgery in some cases



# DEVELOP


## Developing Testing Solutions for Today's Clinical Challenges

Asuragen is one of the few molecular diagnostics companies capable of spanning the diagnostic development spectrum from biomarker discovery and clinical validation to manufacturing and global commercialization.

- Our genomic services group has translated over 20 biomarker projects into analytically and clinically validated tests for pharmaceutical partners
- We have the flexibility and know-how to develop tests on the most appropriate diagnostic platform — our tests run on 12 of the leading molecular platforms available worldwide
- Ten of the top 12 pharmaceutical companies have partnered with us to accelerate their drug development programs

### SuraSeq<sup>™</sup>

- Our SuraSeq<sup>™</sup> service brings next generation sequencing into the clinical laboratory and represents the power of our genomic capabilities
- Pre-built and custom-designed panels are optimized for FFPE and FNA on multiple platforms
- CLIA SuraSeq<sup>™</sup> panels support clinical trials with on-demand confirmation testing for validation of clinically relevant mutations



# DIAGNOSE

## Diagnosing Disease and Improving Patient Management

Asuragen's products and technologies guide more than 15 million medical decisions for patients each year and our oncology and genetic disease assays are used by more than half of the NCI Centers of Excellence. From monitoring the effectiveness of leukemia treatment to informing reproductive decisions to optimizing surgical approaches in thyroid cancer, the diagnostics Asuragen brings to market are improving patient care and personalizing treatment. In addition, our market-leading test for Fragile X has radically changed the way the FMR1 gene mutations are detected.

### AmplideX<sup>™</sup> FMR1

- Market-leading test for FMR1 gene mutations associated with Fragile X, autism spectrum disorder and infertility
- Novel methodology for amplification of a notoriously challenging DNA sequence
- Dramatically reduces the time to result from 10 days to only 9 hours and increases sensitivity 875-fold

## Built for Companion Diagnostics


By harnessing the discovery, development and diagnostic capabilities across the company's divisions (Genomic Services, CLIA Laboratory Services and Diagnostic Products), Asuragen brings to our partners a seamless development process for companion diagnostics. With a deep understanding of the drug development process matched with proven molecular diagnostic capabilities, Asuragen is able to shorten the companion diagnostics development cycle, reducing costs while improving the likelihood of regulatory approval for our partners.

### BCR/ABL1<sup>™</sup> Quant

- A real-time PCR technology developed for standardized monitoring of treatment response in chronic myeloid leukemia (CML)
- Exquisite sensitivity critical for deeper molecular responses now achieved in CML patients on second-generation tyrosine kinase inhibitors

# Asuragen Heritage in Molecular Diagnostics

A carve-out of Ambion, Asuragen continues a legacy of leadership in the molecular diagnostics arena and a proprietary position in the application of miRNA technology for diagnostics. Today, Asuragen's products, services and technologies drive countless patient management decisions across oncology, genetic disease and other molecular testing modalities. In the future, we envision the company's development of miRNA-based clinical diagnostics will help transform medicine by improving clinical outcomes and health economics.



## The Asuragen Team

Based in beautiful Austin, Texas, Asuragen is made up of an incredibly talented group of down-to-earth scientists and professionals with experience, drive and creativity. From top to bottom, Asuragen is comprised of employees with a diverse blend of experience and disciplinary skills focused on bold ideas and the determination to see them through.



Asuragen, Inc. | 2150 Woodward St., Suite 100 | Austin, TX 78744 USA

[www.asuragen.com](http://www.asuragen.com)

January 2013